At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 23, 2026 at 16:10 ET
Dyne Therapeutics has filed its definitive proxy statement for the upcoming annual shareholder meeting. The filing is routine and contains no material changes or unexpected events. The company is seeking shareholder approval for director elections, executive compensation, and auditor appointment.
- Routine proxy filing for annual shareholder meeting
- No material changes or unexpected events disclosed
- Items include director elections, executive compensation, and auditor appointment
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access